CRMD — CorMedix Inc.

CRMD Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $128.6 million, driven primarily by DEFENCATH ($91.2 million) and Melinta portfolio contributions ($37.4 million).
• Full Year 2025 Revenue: $401.3 million (pro forma), with DEFENCATH generating $258.8 million.
• Operating Expenses: Q4 operating expenses rose to $48.2 million from $17.1 million year-over-year, reflecting the expanded cost structure post-Melinta acquisition.
• Net Income: $14.0 million in 2025, impacted by a non-cash tax expense of $42.4 million.
• Adjusted EBITDA: Q4 adjusted EBITDA was $77.2 million, consistent with guidance.
• Cash Position: Ended Q4 with $148.5 million in cash and short-term investments, supported by strong operating cash flow of nearly $100 million.

2. Strategic Updates and Business Highlights:

• Acquisition of Melinta Therapeutics: Completed in Q3 2025, contributing to revenue growth and operational synergies of $35 million achieved during the year.
• DEFENCATH Strategy: Focus on maintaining patient utilization rates post-TDAPA transition to bundled reimbursement starting July 1, 2026.
• Clinical Development: Progress on RIZEAO for prophylaxis of invasive fungal infections, with Phase III RESPECT study data expected in 2026. DEFENCATH is also in a Phase III study for preventing CLABSI in TPN patients.
• Market Opportunity: RIZEAO estimated market potential of $2.5 billion; DEFENCATH for TPN estimated between $500 million and $750 million.

3. Forward Guidance and Outlook:

• DEFENCATH Guidance: For 2026, projected revenue of $150 million to $170 million; for 2027, $100 million to $125 million.
• Full Year 2026 Financial Guidance: Total revenue expected between $300 million and $320 million, with adjusted EBITDA of $100 million to $125 million.
• Focus on Growth: Emphasis on expanding customer base, especially with Medicare Advantage providers and new potential customers in both inpatient and outpatient settings.

4. Bad News, Challenges, or Points of Concern:

• Reimbursement Risks: Transition to bundled reimbursement may lead to price erosion in Q4 2026, impacting revenue.
• Legislative Uncertainty: Ongoing discussions regarding TDAPA extension are speculative, with potential delays due to broader political events.
• Customer Concentration: Heavy reliance on a few large dialysis organizations for DEFENCATH sales could pose risks if relationships or market dynamics change.

5. Notable Q&A Insights:

• Customer Engagement: Management reported positive discussions with dialysis customers regarding supply and pricing strategies for DEFENCATH.
• RIZEAO Data Utilization: Potential to leverage positive Phase III data to engage payers, emphasizing benefits such as reduced drug-drug interactions and hospitalizations.
• Inpatient Opportunities: Management indicated that growth in the inpatient segment for DEFENCATH is expected to be slower compared to outpatient, with a focus on onboarding additional customers.
• Operational Cash Flow: Strong cash flow is anticipated, but potential inventory stockpiling and accrued rebates may impact cash flow dynamics in 2026.

Overall, CorMedix Inc. is positioned for growth in 2026, but faces challenges related to reimbursement changes and market concentration risks.